Sciclone Pharmaceut (SCLN) 13.63 $SCLN Sciclone

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 8:25 AM

Sciclone Pharmaceut (SCLN) 13.63 $SCLN

Sciclone Pharmaceuticals Has Returned 70.9% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Jun 10, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 70.93% as of today's recent price of $13.63.
SCLN: 13.63 (-0.36)

Shares of SCLN Up 74.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:11AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 74.17% as of today's recent price of $13.89.
SCLN: 13.63 (-0.36)

Sciclone Pharmaceuticals Shares Up 62.9% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Thu May 26, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 62.88% as of today's recent price of $12.99.
SCLN: 13.63 (-0.36)

AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 55.36 (-1.51), SCMP: 11.70 (-0.27), SCLN: 13.63 (-0.36), BIOD: 0.34 (unch)

Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 64.4% (SCLN)
Comtex SmarTrend(R) - Wed May 11, 12:42PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 6 months, Sciclone Pharmaceuticals has returned 64.39% as of today's recent price of $13.11.
SCLN: 13.63 (-0.36)

SciClone Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016.
SCLN: 13.63 (-0.36)

SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016
PR Newswire - Mon Apr 25, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
SCLN: 13.63 (-0.36)

Shares of SCLN Up 62.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 19, 12:15AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 62.51% as of today's recent price of $12.96.
SCLN: 13.63 (-0.36)

Sciclone Pharmaceuticals Shares Up 55.3% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Mon Apr 11, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 55.30% as of today's recent price of $12.39.
SCLN: 13.63 (-0.36)

Shares of SCLN Up 37.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 01, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 37.62% as of today's recent price of $10.98.
SCLN: 13.63 (-0.36)

Look for Shares of Sciclone Pharmaceuticals to Potentially Pullback after Yesterday's 13.34% Rise
Comtex SmarTrend(R) - Thu Mar 31, 3:35PM CDT
Sciclone Pharmaceuticals (NASDAQ:SCLN) traded in a range yesterday that spanned from a low of $10.35 to a high of $10.99. Yesterday, the shares gained 13.3%, which took the trading range above the 3-day high of $9.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SCLN: 13.63 (-0.36)

WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Wed Mar 30, 5:24PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, April 1:
WBMD: 62.90 (-1.28), TMO: 151.80 (-2.35), SUNE: 0.34 (unch), SCLN: 13.63 (-0.36), MHFI: 107.92 (+1.16), AFFX: 14.01 (+0.02)

SciClone To Present At Needham Healthcare Conference On April 13, 2016
PR Newswire - Wed Mar 30, 5:00AM CDT
FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 15th Annual Needham Healthcare Conference at 8:00 am ET on Wednesday, April 13, 2016, at the Westin Grand Central Hotel in New York City.
SCLN: 13.63 (-0.36)

OxySure Therapeutics (OXYS) May Be Undervalued Compared to Others in Biotech Space
ACCESSWIRE - Mon Mar 21, 8:01AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 21, 2016 / OxySure Therapeutics Inc. (OTCQB: OXYS), developer of oxygen-from-powder technology and related medical solutions, has come a long way over the past year. Management anticipates reaching a $10 million annual run rate and achieving breakeven later this year. With 14 consecutive quarters of revenue growth, the company has a long track record of increasing shareholder value.
SRDX: 23.19 (-0.11), CFMS: 7.49 (-0.01), GKOS: 27.29 (+0.33), BEAT: 16.69 (+0.15), SCLN: 13.63 (-0.36)

SciClone Reports 2015 Financial Results
PR Newswire - Thu Mar 10, 3:05PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter and year ended December 31, 2015.
SCLN: 13.63 (-0.36)

LifeSci Capital Initiates Coverage of SciClone
ACCESSWIRE - Tue Mar 08, 1:45PM CST
Profitable Specialty Pharmaceutical Company with Steady Revenue Growth; Report Available here: http://www.lifescicapital.com/equity-research/sciclone/
BAX: 44.49 (-0.26), PFE: 35.29 (-0.02), SCLN: 13.63 (-0.36)

27.3% Return Seen to Date on SmarTrend Sciclone Pharmaceuticals Call (SCLN)
Comtex SmarTrend(R) - Mon Mar 07, 5:13PM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 4 months, Sciclone Pharmaceuticals has returned 27.27% as of today's recent price of $10.15.
SCLN: 13.63 (-0.36)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

CURE Intl and Thoughtworks Step Into Digital Era

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

RF MEDICAL Expands into Europe with New CE Certification

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...